Bio

Sumitovant Biopharma a new, global biopharmaceutical company based in New York City and London. It is the parent company of five biopharmaceutical companies: Myovant, Urovant, Enzyvant, Altavant and Spirovant. Our companies have a robust pipeline of innovative drug treatments targeting a broad range of diseases. With a technology-enabled approach to drug discovery, development and commercialization, we remove friction from the process of bringing promising new compounds to market. I am the CEO of Sumitovant and am also the founder of Myrtle Potter & Company, LLC, a healthcare and life science advisory firm that has operated since 2005, and continues to operate under the guidance of others. Myrtle Potter & Company advises public and private life science corporations and boards of directors on corporate strategy, product development and commercialization. MP&C is known for driving enterprise value for our clients. I am on the boards of a number of Sumitovant Family of companies, Liberty Mutual Insurance Group and Axsome Therapeutics. I am also on the board of trustees of The University of Chicago. I formerly served on the boards of Amazon, Medco, Express Scripts, Insmed, Rite Aid, Express Scripts, Everyday Health, eV3 and FoxHollow Technologies. I also served on Dean’s Advisory Council for the Stanford Graduate School of Business (6 years) and on the Financial Oversight Committee for the California Institute for Regenerative Medicine Foundation (6 years). Earlier in my career I was president and COO of Genentech, Inc. Prior to joining Genentech I served as president of Bristol-Myers Squibb’s U.S. Cardiovascular/Metabolics business, and earlier was vice president of a Merck business unit. While at Merck I also started the drug company Astra/Merck Inc. Astra/Merck, Inc. through a series of transactions would operate globally as AstraZeneca.